30.33
Instil Bio Inc (TIL) 最新ニュース
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com India
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Nasdaq
Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus
Instil Bio appoints new Chief Medical Officer - Investing.com
Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan
Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia
Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com Canada
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
Instil Bio (TIL) Shares Surge on New Clinical Development Plans - GuruFocus
Instil Bio stock rises on cancer trial updates (TIL:NASDAQ) - Seeking Alpha
Instil Bio (TIL) Maintains Buy Rating as Price Target is Adjusted | TIL Stock News - GuruFocus
Instil Bio stock price target cut to $105 by H.C. Wainwright - Investing.com Nigeria
Instil Bio (TIL) Price Target Reduced by Analyst | TIL Stock News - GuruFocus
Instil Bio Partners with ImmuneOnco for Cancer Therapy - TipRanks
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | TIL Stock News - GuruFocus
Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn - marketscreener.com
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ... - Bluefield Daily Telegraph
Instil Bio's Lung Cancer Drug Achieves 23% Response Rate in Phase 2 Trial, Major Results Expected in Late 2025 - Stock Titan
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
(TIL) Investment Analysis - news.stocktradersdaily.com
Instil (TIL) Projects Financial Stability Through 2026 | TIL Sto - GuruFocus
Instil Bio, Inc. SEC 10-Q Report - TradingView
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
大文字化:
|
ボリューム (24 時間):